Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK.
J Cell Mol Med. 2009 Oct;13(10):4090-103. doi: 10.1111/j.1582-4934.2009.00906.x. Epub 2009 Sep 14.
Breast cancer is a genetic disease caused by the accumulation of mutations in neoplastic cells. In the last few years, high-throughput microarray-based molecular analysis has provided increasingly more coherent information about the genetic aberrations in breast cancer. New biomarkers and molecular techniques are slowly becoming part of the diagnostic and prognostic armamentarium available for pathologists and oncologists to tailor the therapy for breast cancer patients. In this review, we will focus on the contribution of breast cancer somatic genetics to our understanding of breast cancer biology and its impact on breast cancer patient management.
乳腺癌是一种由肿瘤细胞中突变积累引起的遗传疾病。在过去的几年中，高通量基于微阵列的分子分析为乳腺癌中遗传异常提供了越来越多连贯的信息。新的生物标志物和分子技术正在逐渐成为病理学家和肿瘤学家可用于为乳腺癌患者定制治疗的诊断和预后工具的一部分。在这篇综述中，我们将重点关注乳腺癌体细胞遗传学对我们理解乳腺癌生物学的贡献及其对乳腺癌患者管理的影响。
